BPC-157
Also known as: Body Protection Compound 157 · Bepecin · PL 14736
A synthetic 15-amino-acid peptide derived from a fragment of human gastric juice protein, studied for tissue-repair, gut-brain-axis, and emerging neuroprotective and cognitive-relevant effects.
BPC-157 is a 15-amino-acid gastric-juice-derived peptide with tissue-repair and emerging gut-brain-axis neuroprotective effects; UK research-chemical status.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Short plasma half-life; local and central effects extend beyond exposure
Section 1
Overview
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a fragment of human gastric juice protein. It was developed originally as a candidate therapeutic for gastrointestinal inflammatory conditions — inflammatory bowel disease, gastric ulcers — where the parent gastric-juice protein has documented protective effects. The synthesised peptide has expanded far beyond that origin in the research-peptide literature, appearing in tissue-repair, angiogenesis, and — more recently — gut-brain-axis and neuroprotective research contexts.
The peptide is included on this reference because a growing body of research addresses its CNS effects. The gut-brain axis has emerged as a substantial research frontier in cognitive and neuropsychiatric research over the past decade, and BPC-157's dual identity as a gut-active and centrally-active peptide places it at the intersection of that axis. Reports of neuroprotection in ischaemic injury models, effects on serotonin and dopamine systems, and possible cognitive and mood effects in animal work have expanded its research footprint substantially.
The evidence base is uneven. The tissue-repair and gastrointestinal-inflammation literature is well-established, with multiple independent replications and a body of mechanistic understanding. The cognitive and neuroprotective literature is thinner and dominated by a smaller group of research programmes. Independent Western replication is limited for many of the more distinctive claims.
Section 2
Discovery & History
- Isolated from human gastric juice as part of the Sikirić laboratory programme at the University of Zagreb in the 1990s, alongside the parent gastric-juice protein from which the fragment derives.
- Entered clinical evaluation as a therapeutic candidate for inflammatory bowel disease (as PL 14736) under the Pliva Pharmaceuticals development programme; the clinical evaluation did not progress to marketing authorisation but generated a substantial safety database.
- Continued academic research through the 2000s and 2010s expanded the pharmacological characterisation into tissue repair, angiogenesis, tendon and ligament healing, and — more recently — CNS effects.
- In the research-peptide market, BPC-157 has become one of the highest-demand compounds; substantial commercial supply exists, though quality varies dramatically across the vendor landscape.
- The compound's regulatory status in the UK remains that of an unlicensed research chemical; no marketing authorisation has been granted or actively pursued.
Section 3
Mechanism of Action
- 1Angiogenic effects — measurable increases in VEGF expression, endothelial-cell migration, and neovascularisation in tissue-repair and injury models, providing a mechanistic root for the tissue-healing and neuroprotection claims.
- 2Anti-inflammatory effects across multiple tissue systems — reduction of pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6), attenuation of NF-κB signalling, and modulation of macrophage phenotype in injury models.
- 3Nitric oxide (NO) system modulation — BPC-157 interacts with the NO synthesis pathway, contributing to vasodilatory, angiogenic, and neuroprotective effects.
- 4Neurotransmitter system modulation in the CNS — reported effects on serotonin, dopamine, and GABA systems in animal work, providing plausible mechanistic scaffolds for the mood and cognitive claims that appear in the research-peptide literature.
- 5Gut-brain-axis modulation via effects on the enteric nervous system and vagal signalling — a distinctive mechanistic angle for a peptide with both gastrointestinal and CNS effects.
- 6Reported neuroprotective effects in cerebral ischaemia, TBI, and haloperidol-induced catalepsy models, extending the tissue-repair mechanism into CNS injury contexts.
- 7Effects on BDNF expression reported in some animal work, potentially linking the peptide to the broader BDNF-mediated cognitive-plasticity mechanism that dominates the cognitive-peptide literature.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Tissue-repair effects in muscle, tendon, ligament, and gastrointestinal-mucosa injury models — the flagship claim and the strongest area of the evidence base.
- 2Gut-mucosa protection and reduction of experimental colitis severity in animal models — the original therapeutic-indication research angle.
- 3Angiogenic effects supporting wound healing and post-ischaemic recovery in cerebrovascular and cardiovascular research models.
- 4Reported neuroprotective effects in cerebral ischaemia and traumatic brain injury animal models.
- 5Anti-inflammatory effects with broad application across musculoskeletal, gastrointestinal, and CNS injury models.
- 6Reported cognitive and mood effects in some animal work, potentially via serotonin, dopamine, and BDNF-related mechanisms.
- 7Gut-brain-axis relevance — the peptide's dual gut and CNS activity positions it distinctively in gut-brain research.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / oral (research) | Microgram to milligram range in animal protocols | Once or twice daily in most published research | Course lengths vary from 5-day acute to 6+ week chronic protocols |
Note: Widely-quoted 'research protocols' from non-peer-reviewed sources should not be conflated with the peer-reviewed literature.
Section 6
Administration Routes
- Subcutaneous administration — the reference route in most published animal research and the practical route for reproducible pharmacokinetic characterisation.
- Oral administration is reported to produce systemic and local gut effects; the peptide's relative resistance to gastrointestinal proteolysis is one of the distinctive features but has not been fully mechanistically characterised.
- Intraperitoneal administration in some animal research contexts.
- Topical application in tissue-repair research on external tissues.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in the animal research at studied doses across multiple tissue systems and course lengths.
- · The clinical-evaluation programme (PL 14736 for IBD) generated a substantial acute-safety database with no significant tolerability signals at the doses studied.
- · Mild injection-site reactions occasionally reported at subcutaneous administration sites.
- · No documented dependence, tolerance, or withdrawal phenomena in the published research.
Rare / theoretical
- · Long-term systemic-administration safety data is limited — most published research is short-course; chronic multi-year use has not been characterised.
- · The peptide's angiogenic and anti-inflammatory effects raise theoretical concerns in the context of active malignancy or angiogenic-driven pathologies, though no documented clinical cases exist.
- · The vendor-quality landscape for commercial BPC-157 is highly variable — counterfeit, mis-labelled, and contaminated material is common in the grey-market supply.
- · Theoretical interactions with anti-angiogenic pharmaceuticals (bevacizumab, aflibercept) given the pro-angiogenic mechanism.
Contraindications
- · Not authorised for human use in the UK — supply for human consumption is prohibited under the Human Medicines Regulations 2012.
- · Active malignancy — theoretical contraindication via the pro-angiogenic and mitogenic-adjacent mechanisms.
- · Pregnancy and lactation — no controlled human data.
- · Concurrent anti-angiogenic pharmaceutical therapy — pharmacodynamic incompatibility.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Research chemical only; supply for human consumption is prohibited.
European Union
Not approved by the EMA. Historical clinical evaluation programme in inflammatory bowel disease did not progress to approval.
Section 9
Clinical Studies Summary
BPC-157 in gastrointestinal mucosa protection
Foundational Sikirić-group animal research demonstrating protection against experimental gastric ulceration, reduced severity of experimental colitis, and accelerated mucosal healing in multiple gastrointestinal injury models. The evidence base that motivated the clinical evaluation programme for the compound in inflammatory bowel disease.
BPC-157 tendon and ligament healing effects
Animal research demonstrating accelerated tendon and ligament healing in experimental transection models, with the effect involving angiogenic, anti-inflammatory, and direct trophic mechanisms operating in concert. The mechanistic scaffold for the peptide's widespread use in musculoskeletal research contexts.
BPC-157 in cerebral ischaemia neuroprotection
Rodent model of cerebral ischaemia with BPC-157 administration reporting reduced infarct volume, preserved neurological function, and improved histological outcome versus vehicle controls. Extended the mechanistic evidence base into CNS injury contexts and provided one of the first neuroprotective data points for the peptide.
BPC-157 effects on serotonin and dopamine systems
Neurochemistry study characterising the effects of BPC-157 on serotonin and dopamine turnover in animal models, reporting modulation of both systems at pharmacologically-relevant doses. Provided a mechanistic angle for the mood and cognitive claims that appear in the broader research-peptide literature.
BPC-157 clinical evaluation in inflammatory bowel disease (PL 14736)
Phase II clinical evaluation in inflammatory bowel disease conducted under the Pliva Pharmaceuticals development programme, reporting acceptable safety and tolerability but insufficient efficacy to support progression to Phase III. The clinical experience contributes to the safety database but did not lead to regulatory approval.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing BPC-157 for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain BPC-157 from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.